POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measureSecondary measure, the 50% response ...

Praxis Precision Medicines said on Monday its experimental epilepsy drug failed to meet the ​main goal of a mid- to late-stage ‌study, prompting it to pause enrollment in another ongoing study while ...

Praxis Precision Medicines said vormatrigine, a treatment it is developing for certain seizures and epilepsy, did not meet its primary endpoint in a recent trial. The biopharmaceutical company said ...

In Q1 2026, Praxis Precision Medicines reported that the FDA accepted New Drug Applications for ulixacaltamide in essential tremor and relutrigine in developmental and epileptic encephalopathies, with ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Praxis Precision Medicines has been blindsided by a recommendation to stop a phase 3 essential tremor trial. Two months after CEO Marcio Souza said the chances of the trial being futile were “less ...

View Praxis Precision Medicines, Inc. PRAX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Shares of Praxis Precision Medicines declined after vormatrigine, a treatment the company is developing for certain seizures and epilepsy, didn't meet its primary endpoint in a recent trial. The stock ...